Mapi Pharma

Formulations That Meet Unmet Patient Needs

Focused on long acting
depot injections

Developing Finished Dosage Forms and a Portfolio of APIs

Fully integrated GMP
manufacturing facilities

Pipeline of Multiple Late Stage Products

In Phase III for RMS and Phase II for
PPMS for treating MS

We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.

Focus

Our main focus is on developing long acting depot injectable drugs.

Programs

Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica^®) for pain.

Latest News

Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Sclerosis (MS) at ECTRIMS 2021

October 11, 2021

Results for Glatiramer Acetate (GA) Depot Phase IIa study in patients with primary progressive multiple sclerosis, and novel anti-BMP for remyelination treatment in MS will be presented ECTRIMS 2021 Digital Experience will be held virtually Oct. 13-15, 2021 ...

Mapi Pharma Provides Enrollment Update in Phase III GA Depot Clinical Trial

December 21, 2020

Patient recruitment in Phase III trial has surpassed 60% Trial is expanded to Israel with first clinical site at Tel Aviv Medical Center NESS ZIONA, Israel – Dec. 21, 2020 – Mapi Pharma Ltd., a fully integrated, late clinical stage biopharmaceutical company,...